Juhi Gor
YOU?
Author Swipe
View article: Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia
Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia Open
Clonal evolution (CE) is a driving force behind the development and progression of acute myeloid leukemia (AML). Advances in molecular and cytogenetic assays have improved the depth and breadth of detection of CE in AML, which is defined h…
View article: The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia
The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia Open
Introduction The use of venetoclax in acute myeloid leukemia (AML) has become routine - following FDA approval, approximately half of patients with AML have received venetoclax. However, the outcomes of the timing of venetoclax initiation …
View article: Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia
Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia Open
Background: The diagnosis and management of acute myeloid leukemia (AML) have transformed in recent years with an improved understanding of leukemogenesis and improved methods of measurable residual disease (MRD) detection. Current treatme…
View article: Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice
Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice Open
Introduction: The treatment landscape for relapsed or refractory acute myeloid leukemia (RR AML) is quickly evolving, guided by routine genetic profiling at diagnosis and relapse. In recent years, there has been a surge in FDA approvals fo…
View article: Comprehensive Molecular Stratification of Patients with AML Treated with CPX-351
Comprehensive Molecular Stratification of Patients with AML Treated with CPX-351 Open
Background: Liposomal cytarabine-daunorubicin (CPX-351) is approved for treatment of acute myeloid leukemia (AML) with myelodysplasia (MDS)-related changes and therapy-related AML. CPX-351 induction has been observed to result in longer pe…
View article: Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Open
Relapsed or refractory acute myeloid leukemia (AML) is associated with poor outcomes and resistance to therapy. The addition of venetoclax, a BCL-2 antagonist, to lower-intensity therapies results in improved survival in the first-line set…
View article: Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia Open
Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid pace in recent years. The combination of venetoclax with a hypomethylating agent prolonged survival in clinical trials when compared to hypomethylating agent mono…